# Forcefield Ventures

> Forcefield Ventures is a VC fund backing Pharmaceutical, Medical and Biotechnology. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 3
- Last investment: Jul 2023
- Lead investor: 33%
- Last updated: Aug 2026

Forcefield Ventures is a venture capital firm.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Pharmaceutical | 2 | 67% |
| Medical | 1 | 33% |
| Biotechnology | 1 | 33% |
| Information Technology | 1 | 33% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 2 | 67% |
| Series A | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 2 | 67% |
| United States | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Amide Technologies | Amide synthesizes peptides that are difficult to obtain through existing means, bridging the gap between traditional solid phase peptide synthesis and biological expression. By using unnatural amino acids and artificial protein backbones, our team is expanding what is biologically possible. Amide’s Automated Fast Flow Peptide Synthesizer (AFPS)leverages flow to dramatically improve solid phase peptide synthesis. Using the power of flow, we can generate highly reactive intermediates in situ, maintain excellent heat and mass transfer, and achieve much better synthetic outcomes than alternative SPPS methods. With all these advantages, AFPS allows biopharma pioneers to dramatically re-think what’s possible. Let Amide broaden your horizons with better, faster synthesis. | $7.5M | Series A | Jul 28, 2023 |  |
| CytoCan Corp. | CytoCan Corp. operates as a biotechnology company that focus on the research and development of multi-specific fusion protein drugs. | $1.5M | Seed | Feb 07, 2023 |  |
| META Pharmaceuticals | META Pharmaceuticals is a cutting-edge drug development company specializing in autoimmune diseases. | $15M | Seed | Jun 13, 2022 |  |

3 of 3 investments shown.

## Co-investors
- [XtalPi](https://shizune.co/investors/profile/xtalpi) — VC Fund, 2 deals together
- [BOPU](https://shizune.co/investors/profile/bopucoin) — VC Fund, 1 deal together
- [Dinghang Capital](https://shizune.co/investors/profile/dinghang-capital) — VC Fund, 1 deal together
- [Fangyuan Capital](https://shizune.co/investors/profile/fangyuan-capital) — VC Fund, 1 deal together
- [IMO Ventures](https://shizune.co/investors/profile/immersion-ventures) — VC Fund, 1 deal together
- [New Industry Ventures](https://shizune.co/investors/profile/new-industry-ventures) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Forcefield Ventures invest in?

Forcefield Ventures invests primarily in Pharmaceutical, Medical and Biotechnology startups, most often at Seed and Series A stage. Most of the 3 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Forcefield Ventures last invest?

The most recent investment recorded for Forcefield Ventures closed in Jul 2023. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co